TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News How the GARDian3 trial could define the next commercial frontier in ophthalmic gene therapy Discover how Ocugen, Inc.’s GARDian3 trial could redefine the commercial future of ophthalmic gene therapy and what investors should watch next. bySoujanya RaviApril 4, 2026